The regulator of the serine biosynthesis pathway, phosphoglycerate dehydrogenase, is a candidate therapeutic target for the elimination of advanced or metastatic ccRCC resistance to HIF-2α antagonists [15]. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.